Pronounce: RE-ti-FAN-li-mab
Classification: Programmed death receptor-1 (PD-1) blocking antibody
This medication is a programmed death receptor-1 (PD-1)–blocking antibody. It is a type of monoclonal antibody therapy, which works to stimulate (rev up) the immune system to kill cancer cells.
The immune system works by creating antibodies, which are proteins that attach to antigens found on the surface of a cell. The antibody “calls” the immune system to attack the cell it is attached to. Monoclonal antibodies are created in a lab to attach to the antigens found on some types of cancer cells. T-cells are a type of white blood cell that are important to how your immune system works.
Retifanlimab-dlwr binds to the "programmed death receptor" (PD1) found on T-cells to help the immune system find and kill cancer cells.
Retifanlimab-dlwr is given by a single intravenous (IV, into a vein) infusion. The dose and how often you receive the medication will be decided by your care team. This medication can be given for up to 24 months (2 years).
Make sure your care team is aware of all medications (including prescription and over-the-counter), supplements, and vitamins you are taking. Steroids should be avoided while on immunotherapy unless directed by your care team.
Tell your care team about all your medical conditions, including those that are autoimmune in nature (Crohn’s disease, lupus, rheumatoid arthritis, etc.) as these can get worse with immunotherapy. You should also notify your provider if you have had or plan on having an allogeneic stem cell transplant as this medication can worsen a side effect of the transplant called graft-versus-host disease.
There are a number of things you can do to manage the side effects of retifanlimab-dlwr. Talk to your care team about these recommendations. They can help you decide what will work best for you. These are some of the most common or important side effects:
Your red blood cells are responsible for carrying oxygen to the tissues in your body. When the red cell count is low, you may feel tired or weak. You should let your oncology care team know if you experience any shortness of breath, difficulty breathing or pain in your chest. If the count gets too low, you may receive a blood transfusion.
White blood cells (WBC) are important for fighting infection. A lymphocyte is one kind of white blood cell. While receiving treatment, your WBC count can drop, putting you at a higher risk of getting an infection. You should let your care team know right away if you have a fever (temperature greater than 100.4°F or 38°C), sore throat or cold, shortness of breath, cough, burning with urination, or a sore that doesn't heal.
Tips for preventing infection:
This medication can affect the level of sodium (and possibly other electrolytes) in your body. Your levels will be monitored using blood tests. If your levels become too low, your care team may prescribe specific electrolytes to be given by IV or taken by mouth. Do not take any supplements without first consulting with your care team.
This medication can cause liver toxicity, which your oncology care team may monitor for using blood tests called liver function tests. Notify your healthcare provider if you notice yellowing of the skin or eyes, your urine appears dark or brown, or you have pain in your abdomen, as these can be signs of liver toxicity.
Fatigue is very common during cancer treatment and is an overwhelming feeling of exhaustion that is not usually relieved by rest. While on cancer treatment, and for a period after, you may need to adjust your schedule to manage fatigue. Plan times to rest during the day and conserve energy for more important activities. Exercise can help combat fatigue; a simple daily walk with a friend can help. Talk to your healthcare team for helpful tips on dealing with this side effect.
Your healthcare provider can recommend medications and other strategies to help relieve pain.
Exposure of an unborn child to this medication could cause birth defects, so you should not become pregnant or father a child while on this medication. Even if your menstrual cycle stops or you believe you are not producing sperm, effective birth control is necessary during treatment and for 4 months after stopping treatment. You should not breastfeed while taking this medication or for 4 months after the end of treatment.
OncoLink is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through OncoLink should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem or have questions or concerns about the medication that you have been prescribed, you should consult your health care provider.
Information Provided By: www.oncolink.org | © 2025 Trustees of The University of Pennsylvania